We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 0.42% | 35.65 | 35.40 | 35.90 | 36.50 | 34.05 | 36.50 | 425,707 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.25 | 106.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/12/2022 13:38 | Next spike up is well overdue ;-) | broomrigg | |
21/12/2022 13:36 | LOLIf you're a fan of PANR as well as this then you're in for a highly "challenging" 2023!Suggest separating yourself from emotions and take a cold hard look at the prospects of a company which must do a large raise early in H1 next year, nevermind the fact the "product" failed its P3.The fact this thread says "FUTURA a winner for 2015" says it all!!!? | truant2tb1 | |
21/12/2022 13:33 | Thats how they play Spread false information and short | j777j | |
21/12/2022 13:32 | "The product doesn't even work for starters!" Well, that makes two people who have claimed that, both of them liars and fantasists, and known stock bashers. Compared to over 60% of men with ED who have tested it in clinical and real world tests and confirmed that it works. | petroc | |
21/12/2022 13:30 | Anyone who calls other people petal,well sums him up Oh and btw it works great Consumer In-Use Test Cooper, as part of its due diligence process, conducted a consumer marketing Home Use Test ("HUT") in the United Kingdom, France and the Netherlands whereby individuals self-diagnosed with ED were provided with a four-pack sample of MED3000. The in-use results were in line with findings published in 2019 in Futura's clinical study FM57 which showed that over two thirds of patients experienced a clinically meaningful benefit from using MED3000 in a controlled clinical setting. MED3000 performed well in the real world, consumer HUT setting, with the majority of men with ED, other than men suffering from severe ED with significant co-morbidities, seeing an improvement in erectile performance and underlining the product's potential as a highly effective, safe, clinically proven, topical treatment for ED. | j777j | |
21/12/2022 13:22 | We genuinely don't. I've read all the information out there and don't believe this company to be worth anything near 52p The product doesn't even work for starters! | truant2tb1 | |
21/12/2022 12:41 | Truant and lbo work together to try spread misinformation and doubt Sad I know but thats their game Cant wait to see their faces when the FDA approval comes through | j777j | |
21/12/2022 12:33 | Cat Jeeves whoever that is needs to take some grammar lessons eh? I just saw this rather more concise article Futura Medical Price Target 121p Positive progress continues at Futura Medical, with MED3000 now under formal review at the FDA and decision on marketing authorisation expected by the end of Q1 2023. Management continues to set the foundations for the launch and commercial scale up of MED3000, with launches in Europe to commence in H1 2023 and in the Middle East later next year. We believe Eroxon®, the brand name of MED3000, has the potential to become a global name as a potential first-in-class OTC treatment for erectile dysfunction. We reiterate our BUY and our 121p target price, and point to the FDA decision and the conclusion of a US licensing agreement as potential catalysts for further value creation. Regulatory progress continues The FDA has formally accepted the regulatory submission dossier of MED3000, indicating that it has successfully passed the initial technical screening setting. This sets in motion a decision on US marketing authorisation by the end of Q1 2023. This is in line with previously announced guidelines. We believe that MED3000 has the potential to be a first-in-class OTC treatment for erectile dysfunction and that the strength of clinical data to date suggests a high likelihood of approval. Regulatory progress continues elsewhere and MED3000 has recently received marketing authorisation in three Middle East countries, including the significant market of the UAE. Initial launches and further approvals in the Middle East are expected as we head into 2023. Overall, this highlights that the building blocks continue to be laid for Eroxon® to become a global brand. Stage is set for initial launches in 2023 Encouragingly, Futura’s European & UK partner, Cooper Consumer Health, looks set to commence an initial launch of Eroxon®, the brand name of MED3000, in H1 2023. In September and in support of a launch, we have already seen first production orders from Cooper. More recently, after the market authorisation of MED3000 in three Middle East nations, Labetec Pharma, Futura’s distribution partner in the Middle East, has also made first production orders for a launch planned for 2023. {Liberum) | j777j | |
21/12/2022 12:06 | Just seen an article on Shareprophets - TW's site - on FUM Look forward to reading!! TW red flagging a company is always a worry | truant2tb1 | |
21/12/2022 10:21 | Over 60% of men, WHO HAVE ACTUALLY USED MED3000 IN 2 CLINICAL TRIALS AND A REAL WORLD TEST, confirmed that MED3000 worked for their ED. LiarBO, who has never even seen MED3000, let alone used it, says it doesn't work. Boo hoo! | petroc | |
21/12/2022 10:18 | Luckily, MED3000 had an excellent safety profile with very low incidence of adverse events in males and female partners. Results demonstrated that MED3000 has the potential to be an effective, clinically proven, topical treatment for erectile dysfunction. | petroc | |
21/12/2022 09:41 | The objective data over many years of use. After appropriate assessment and correct use has proven Viagra to be effective and safe. Viagra has a well-established efficacy and tolerability profile. From its introduction in 1998 to 2016, over 64m men worldwide were treated with sildenafil citrate. 'The safety profile of sildenafil citrate is based on over 9,570 patients in 74 double blind placebo-controlled clinical studies as well as postmarketing surveillance that has been gathered over 10 years.' And correlation is not causation.Viagra studies have even showed men taking it live longer.https://www.f | lbo | |
20/12/2022 22:46 | LiarBO seems to base his opposition to MED3000 entirely on a potential placebo effect. Although over 60% of men who have actually used it in clinical trials and a real world test all confirm that it works, LiarBO, who has never seen or used MED3000, claims it doesn't work, and that the results all point to a fantasy placebo response. He then links reams of rubbish about PE in an attempt to 'prove' his assertion. Unfortunately for LiarBO there is an increasing swell of opinion in medicine to disprove the myth of placebo. '... A good first step would be to see the placebo response for what it is a conceptual myth that sustains a broken medical system and covers up what we are really seeking our inherit healing capacity now freed by understanding how deeply meaning infuses us all.' If anyone cares to read about it, try this: target='window'>h At this point, LiarBO will be sticking his fingers in his ears shouting, 'No, no, no! They're all proven liars!' which he says about everyone who doesn't agree with him. And another thing - just because something has the potential to cause a placebo response, doesn't mean it does. A bit like just because you're paranoid, it doesn't mean they're NOT out to get you! 'The placebo response is a myth. It does not exist in reality, and continuing to name it is hindering the optimal application of science to healing in medicine. On the surface, it is obvious that, when defined as a biological response to an inert pill (like a sugar pill), the idea of a response to a placebo is impossible. Inert treatments by definition do not produce responses. So why do we continue to ponder why people get better from taking inert substances and base our acceptance of legitimate treatments on demonstrating that they go beyond that response?' Answer - vested interest. Read the article, all is explained. | petroc |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions